Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Lipid-derived Compounds in the Human Body
Receptor-mediated Endocytosis
Coronary Artery Disease V: Interprofessional Care
Blood Studies for Cardiovascular System III: Serum Lipid Profile
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Mar 30, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks
Published on: March 17, 2023
Maryam Darabi1, Isabelle Guillas-Baudouin1, Wilfried Le Goff1
1UMR INSERM-UPMC 1166 ICAN, Pavillon Benjamin Delessert, Hôpital de la Pitié, 83 boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
Reconstituted HDL (rHDL) therapies show promise for cardiovascular disease. Incorporating phosphatidylserine and other negatively-charged phospholipids into rHDL enhances its anti-atherosclerotic functionality, offering new therapeutic avenues.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: